Anxiety, Depression and Quality of Life in Neuroendocrine Neoplasm Patients: Insights from Regression and Network Analysis
Neuroendocrinology · 09.04.2026 · 1-14
DOI: 10.1159/000551891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroendocrinology, online erschienen am 09.04.2026. Verfasst von Kuan Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Quality of Life, Depression, Neuroendocrine Tumors, Anxiety. Die Arbeit nennt 47 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
Background
Neuroendocrine neoplasms (NENs) are rare, heterogeneous malignancies with increasing incidence and poor survival in China. Beyond physical symptoms, patients frequently experience psychological distress and impaired quality of life (QOL), yet comprehensive evidence remains limited.
Methods
Patients with NENs were recruited from the oncology outpatient clinic at Fudan University Shanghai Cancer Center. Psychological status and QOL were assessed using the Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder Questionnaire-7 (GAD-7), and the Quality-of-Life Questionnaire-Gastrointestinal Neuroendocrine Tumors-21 (QLQ-GI.NET21). Multivariable regression and network analysis were performed.
Results
Among 327 patients, 34.3% exhibited significant depressive symptoms and 34.9% anxiety. Nonmetastatic NEN patients showed higher anxiety, although this finding should be interpreted with caution. Survival time, gender, tumor site, and disease phase significantly influenced anxiety and depression scores. In the gastrointestinal subgroup, G3-grade patients experienced greater distress and poorer QOL. Network analysis revealed a complex interrelationship among anxiety, depression, and QOL dimensions. High-centrality nodes included GAD2 (“uncontrollable worry”), the QLQ-GI.NET21 social function domain, GAD5 (“restlessness”), PHQ9 (“suicide”), and PHQ4 (“fatigue”). Key bridge symptoms were identified as PHQ2 (“sad mood”), GAD5 (“restlessness”), the QLQ-GI.NET21 sexual function domain, PHQ1 (“anhedonia”), and GAD7 (“feeling afraid”). Gender and metastatic status did not significantly affect network structure.
Conclusion
These findings underscore the need for integrated psychological assessments and tailored interventions throughout treatment, particularly for high-risk subgroups. The core symptoms and bridge nodes identified may serve as potential targets for reducing psychological distress in NEN patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychological Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Centre for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, chen0jie@hotmail.com.
- Centre for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, China, chen0jie@hotmail.com.
- Department of Psychological Medicine, Fudan University Shanghai Cancer Center, Shanghai, China, ffww06@163.com.
Zitieren
APA
Zhao, K., Liang, Y., Chen, J., & Feng, W. (2026). Anxiety, Depression and Quality of Life in Neuroendocrine Neoplasm Patients: Insights from Regression and Network Analysis. Neuroendocrinology, 1-14. https://doi.org/10.1159/000551891
Vancouver
Zhao K, Liang Y, Chen J, Feng W. Anxiety, Depression and Quality of Life in Neuroendocrine Neoplasm Patients: Insights from Regression and Network Analysis. Neuroendocrinology. 2026:1-14. doi:10.1159/000551891
BibTeX
@article{Zhao2026,
author = {Zhao, Kuan and Liang, Yun and Chen, Jie and Feng, Wei},
title = {Anxiety, Depression and Quality of Life in Neuroendocrine Neoplasm Patients: Insights from Regression and Network Analysis},
journal = {Neuroendocrinology},
year = {2026},
pages = {1--14},
doi = {10.1159/000551891}
}
EUVIMED